Vimta Labs Ltd

Vimta Labs Employee Stock Options

Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.

Vimta Labs Credit Rating

CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.

Vimta Labs Price Movement Clarification

Vimta Labs clarified that recent increases in its share volume are due to market factors and not related to any undisclosed company information or developments.

Vimta Labs Adverse Business Impact

Vimta Labs reported a cyber security incident affecting its IT infrastructure. The company confirmed operations remain fully functional with no material impact identified thus far.

Vimta Labs Investor Presentation: Key Takeaways

Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.

Call

Guides 25% growth

Vimta Labs Other Announcement

Vimta Labs Ltd filed its quarterly shareholding pattern disclosure for the period ending June 30, 2026, pursuant to SEBI Regulation 31(1)(b).

Vimta Labs Results Update

Vimta Labs announced Q1 FY27 results with total income of ₹112.90 Crore. The company reported a PAT of ₹21.00 Crore for the quarter.

Value

₹112.9 Cr

Vimta Labs Earnings Call: Key Takeaways

Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.

Vimta Labs Q1 FY27 Results: Net Profit ₹21 Cr, Up 11.1% YoY

Vimta Labs Ltd reported revenue from operations of ₹109.1 Cr (+11.8% YoY) and net profit of ₹21 Cr (+11.1% YoY) for Q1 FY27.

Key figure

Net profit ₹21 Cr · +11.1% YoY

Vimta Labs Board Meeting Date

Vimta Labs scheduled a board meeting on July 20, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.

Vimta Labs Dividend

Vimta Labs paid ₹2 per share dividend for FY2025-26, approved at AGM. Payment completed on 04 July 2026 to eligible shareholders.

Vimta Labs Employee Stock Options

Vimta Labs allotted 17,549 equity shares following ESOP exercises. This increases the total paid-up share capital to 44,686,904 shares.

Vimta Labs Employee Stock Options

Vimta Labs allotted 17,549 equity shares under its ESOP 2021 plan. The shares were issued at a face value of ₹2 each.

Vimta Labs Management Change

Vimta Labs re-appointed Sivalinga Prasad Vasireddi as Executive Director for five years. The change is effective from July 01, 2026.

Execution

60 months

Vimta Labs Annual General Meeting

Vimta Labs held its 36th AGM on June 25, 2026. The meeting covered financial statements, dividend declarations, and director appointments.

Vimta Labs Other Announcement

Vimta Labs Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The disclosure outlines the company's ESG performance and sustainability initiatives for the year.

Vimta Labs Annual Report

Vimta Labs Limited submitted its Annual Report and BRSR for FY 2025-26. The 36th Annual General Meeting is scheduled for June 25, 2026.

Vimta Labs Annual General Meeting

Vimta Labs Limited has scheduled its 36th Annual General Meeting for June 25, 2026. The agenda includes dividend declaration and reappointment of the Executive Chairman.

Vimta Labs Earnings Call: Key Takeaways

Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.

Vimta Labs Dividend

Vimta Labs Limited recommended a dividend of ₹2 per equity share for FY 2025-26. The record date is June 18, 2026, with payment scheduled on or before July 8, 2026, subject to shareholder approval.

Vimta Labs Management Change

Vimta Labs Limited has recommended the re-appointment of Dr. S. P. Vasireddi as Executive Chairman for a five-year term effective from July 1, 2026, to June 30, 2031. The appointment is subject to shareholder approval at the upcoming Annual General Meeting. Dr. Vasireddi is the company's founder with over four decades of experience.

Execution

5 years

Vimta Labs Results Update

Vimta Labs Limited reported a 19.5% YoY revenue growth for FY26, reaching ₹416.3 Crore. The company achieved its highest-ever quarterly revenue of ₹112.0 Crore in Q4 FY26. Full-year EBITDA margins stood at 35.8% with a PAT margin of 18.6%, driven by strong performance in Pharma and Food divisions.

Value

₹416.3 Cr

Vimta Labs Earnings Call: Key Takeaways

Vimta Labs reported Q4 FY26 revenue of ₹1,120 Mn and PAT of ₹211 Mn with strong margins across TIC segments.

Vimta Labs Earnings Call: Key Takeaways

Vimta Labs reported strong FY26 performance with Total Income reaching ₹4,163 Mn, up 19.5% YoY, and PAT at ₹775 Mn. Strategy focuses on expanding TIC services across Pharma, Food, and Electronics sectors.

Vimta Labs Q4 FY26 Results: Net Profit ₹21.1 Cr, Up 15.3% YoY

Vimta Labs Ltd reported revenue from operations of ₹109.2 Cr (+15.7% YoY) and net profit of ₹21.1 Cr (+15.3% YoY) for Q4 FY26.

Key figure

Net profit ₹21.1 Cr · +15.3% YoY

Vimta Labs Financial Results

Vimta Labs Limited reported its audited financial results for the year ended March 31, 2026, with total income reaching ₹416.28 Crore. The board recommended a dividend of ₹2 per share and approved incorporating a wholly owned subsidiary in the USA. Additionally, Dr. S. P. Vasireddi was reappointed as Executive Chairman for a five-year term.

Vimta Labs Board Meeting Date

Vimta Labs Ltd has scheduled a Board Meeting for May 6, 2026, to approve audited financial results for Q4 and FY 2025-26. The board will also consider recommending a dividend. The company's trading window is closed until 48 hours after the results announcement.

Vimta Labs Debt & Borrowing: ₹3.33 Cr

Vimta Labs Limited disclosed that it does not fall under the 'Large Corporate' category for FY 2026-27 per SEBI criteria. As of March 31, 2026, the company's outstanding borrowings stood at ₹3.33 Crore. The company maintains an 'A Stable' credit rating from CARE Ratings.

Value

₹3.33 Cr